Results 11 to 20 of about 82,220 (258)
JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis [PDF]
Journal of Immunotherapy and Precision Oncology, 2021 Myelofibrosis (MF) is a myeloproliferative neoplasm hallmarked by uncontrolled blood counts, constitutional symptoms, extramedullary hematopoiesis, and an increased risk of developing acute myeloid leukemia.
Andrew T. Kuykendall, Rami S. Komrokji
doaj +4 more sources
Journal for ImmunoTherapy of Cancer, 2022 During SARS-CoV-2 infection, the innate immune response can be inhibited or delayed, and the subsequent persistent viral replication can induce emergency signals that may culminate in a cytokine storm contributing to the severe evolution of COVID-19. Cytokines are key regulators of the immune response and virus clearance, and, as such, are linked to ...
Gabriel Levy +3 more
doaj +4 more sources
Indian Journal of Dermatology, Venereology and Leprology, 2023 The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway is a key regulatory signaling system for cellular proliferation, differentiation, and apoptosis. In addition, JAK signaling pathway plays critical roles in orchestrating immune response through its interactions with the cytokine receptors and the transcriptions ...
Siba P, Raychaudhuri +1 more
openaire +2 more sources
Journal of Allergy and Clinical Immunology, 2021 Asthma is an inflammatory disease of the airways characterized by intermittent episodes of wheezing, chest tightness, and cough. Many of the inflammatory pathways implicated in asthma involve cytokines and growth factors that activate Janus kinases (JAKs).
Steve N, Georas +3 more
openaire +3 more sources
The safety of JAK-1 inhibitors [PDF]
Rheumatology, 2021 Abstract As efficacy and safety data emerge, differences between JAK inhibitor subclasses are appearing. JAK1 selective drugs, upadacitinib and filgotinib, have broadly come with the same overarching safety recommendations as other immunosuppressive drugs for RA: caution is needed regarding infection risk; monitoring for laboratory ...
Benjamin Clarke +4 more
openaire +3 more sources
The JAK-STAT Pathway and the JAK Inhibitors [PDF]
Journal of Clinical Research in Dermatology, 2020 Dozens of cytokines that bind Type I and Type II receptors use the Janus Kinases (JAK) and the Signal Transducer and Activator of Transcription (STAT) proteins pathway for intracellular signaling, orchestrating hematopoiesis, inducing inflammation, and controlling the immune response.
Ana Paula Galli Sanchez +2 more
openaire +1 more source
JAK inhibitors in autoinflammation [PDF]
Journal of Clinical Investigation, 2018 Interferonopathies are a subset of autoinflammatory disorders with a prominent type I IFN gene signature. Treatment of these patients has been challenging, given the lack of response to common autoinflammatory therapeutics including IL-1 and TNF blockade.
Hal M, Hoffman, Lori, Broderick
openaire +2 more sources
Skin Health and Disease, 2023 Background Janus kinase (JAK) inhibitors are being evaluated as promising upcoming treatments for atopic dermatitis (AD). Objectives To systematically assess the efficacy of oral JAK inhibitors in patients with AD and provide comparisons among JAK ...
Kevin P. Lee +3 more
doaj +1 more source
Life, 2023 Janus kinase (JAK) inhibitors have heralded a paradigm shift in the management of immune-mediated diseases. While their efficacy is well-established, the safety concerns associated with these agents, particularly regarding thromboembolic events (TE ...
Krasimir Kraev +11 more
doaj +1 more source
Janus-kinase Inhibitors in Pathogenesis and Management of Chronic Urticaria: A Review of the Literature [PDF]
Journal of Pediatrics Review, 2023 Background: Chronic urticaria is a long-lasting condition, sometimes with serious comorbidities, severely affecting the quality of life, which makes the patients seek efficient therapies to achieve sustained remissions.
Sepideh Darougar +2 more
doaj